Trial document





This trial has been registered retrospectively.
drksid header

  DRKS00005274

Trial Description

start of 1:1-Block title

Title

Epidemiological community acquired pneumonia study

end of 1:1-Block title
start of 1:1-Block acronym

Trial Acronym

CAPNETZ Study

end of 1:1-Block acronym
start of 1:1-Block url

URL of the Trial

http://www.capnetz.de/html/home

end of 1:1-Block url
start of 1:1-Block public summary

Brief Summary in Lay Language

Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention.

end of 1:1-Block public summary
start of 1:1-Block scientific synopsis

Brief Summary in Scientific Language

Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia.

end of 1:1-Block scientific synopsis
start of 1:1-Block organizational data

Organizational Data

  •   DRKS00005274
  •   2013/09/11
  •   [---]*
  •   yes
  •   Approved
  •   104/01, Ethikkommission der Medizinischen Fakultät der Otto-von-Guericke-Universität Magdeburg
end of 1:1-Block organizational data
start of 1:n-Block secondary IDs

Secondary IDs

  •   U1111-1147-8393 
end of 1:n-Block secondary IDs
start of 1:N-Block indications

Health Condition or Problem studied

  •   CAP; Community Acquired Pneumonia; ambulant erworbenen Pneumonie;
  •   J18 -  Pneumonia, organism unspecified
end of 1:N-Block indications
start of 1:N-Block interventions

Interventions/Observational Groups

  •   Long-term objectives of the basic research part are improvement of CAP-management with respect to therapy, diagnosis and prevention to contribute to a better care of patients with pneumonia
end of 1:N-Block interventions
start of 1:1-Block design

Characteristics

  •   Non-interventional
  •   Epidemiological study
  •   Single arm study
  •   Open (masking not used)
  •   [---]*
  •   Uncontrolled/Single arm
  •   Treatment
  •   Single (group)
  •   N/A
  •   N/A
end of 1:1-Block design
start of 1:1-Block primary endpoint

Primary Outcome

Long-term objectives are improvement of CAP-management with respect to therapy, diagnosis and prevention

end of 1:1-Block primary endpoint
start of 1:1-Block secondary endpoint

Secondary Outcome

to contribute to a better care of patients with pneumonia

end of 1:1-Block secondary endpoint
start of 1:n-Block recruitment countries

Countries of Recruitment

  •   Germany
  •   Netherlands
  •   Switzerland
  •   Denmark
end of 1:n-Block recruitment countries
start of 1:n-Block recruitment locations

Locations of Recruitment

  • University Medical Center 
end of 1:n-Block recruitment locations
start of 1:1-Block recruitment

Recruitment

  •   Actual
  •   2002/10/01
  •   10000
  •   Multicenter trial
  •   International
end of 1:1-Block recruitment
start of 1:1-Block inclusion criteria

Inclusion Criteria

  •   Both, male and female
  •   18   Years
  •   no maximum age
end of 1:1-Block inclusion criteria
start of 1:1-Block inclusion criteria add

Additional Inclusion Criteria

age ≥ 18, infiltrate on chest X-ray, further Inclusion criteria: cough or production of purulent sputum or pathologic lung auscultation (crackles) or fiver

end of 1:1-Block inclusion criteria add
start of 1:1-Block exclusion criteria

Exclusion Criteria

hospital inpatient treatment within the last 28 days, Immune suppressed patients, immunosuppression

end of 1:1-Block exclusion criteria
start of 1:n-Block addresses

Addresses

  • start of 1:1-Block address primary-sponsor
    • Universitätsklinikum Ulm, Institut für Medizinische Mikrobiologie und Hygiene
    • Albert-Einstein-Allee 23
    • 89081  Ulm
    • Germany
    end of 1:1-Block address primary-sponsor
    start of 1:1-Block address contact primary-sponsor
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact primary-sponsor
  • start of 1:1-Block address scientific-contact
    • MUMC+Department of Respiratory Medicine
    • Mr.  Prof. Dr.  Gernot  Rohde 
    • Postbus 5800
    • 6202  Maastricht
    • Netherlands
    end of 1:1-Block address scientific-contact
    start of 1:1-Block address contact scientific-contact
    end of 1:1-Block address contact scientific-contact
  • start of 1:1-Block address public-contact
    • Universitätsklinikum Jena
    • Mr.  Prof. Dr.  Mathias  Pletz 
    • Erlanger Allee 101
    • 07743  Jena
    • Germany
    end of 1:1-Block address public-contact
    start of 1:1-Block address contact public-contact
    end of 1:1-Block address contact public-contact
end of 1:n-Block addresses
start of 1:n-Block material support

Sources of Monetary or Material Support

  • start of 1:1-Block address materialSupport
    • Helmholtz Zentrum München - Deutsches Forschungszentrum für Gesundheit und Umwelt, GmbH
    • Ingolstädter Landstraße 1
    • 85764  Neuherberg
    • Germany
    end of 1:1-Block address materialSupport
    start of 1:1-Block address contact materialSupport
    •   [---]*
    •   [---]*
    •   [---]*
    •   [---]*
    end of 1:1-Block address contact materialSupport
end of 1:n-Block material support
start of 1:1-Block state

Status

  •   Recruiting ongoing
  •   [---]*
end of 1:1-Block state
start of 1:n-Block publications

Trial Publications, Results and other Documents

end of 1:n-Block publications
* This entry means the parameter is not applicable or has not been set.